Grail Inc (GRAL) Stock
Key stats
- Market cap
- $5.65B
- Price / Earnings ratio
- -13.8x
- EPS (TTM)
- -$9.44
- Volume
- Loading
- 52-week high
- $166.48
- 52-week low
- $41.50
- EPS vs analyst estimate
- +26.8%Q3 FY25 · -$2.46 vs -$3.36
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with GRAL
Recent news
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAL
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
GRAL
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
GRAL
2 Growth Stocks to Buy in October
2 Growth Stocks to Buy in October
GRALNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.44
- MACD 12/26/9
- 1.06
- EMA 9 of MACD
- 4.41
- MACD histogram
- -3.36
- SMA 50
- $119.33
- Price above SMA 50
- EMA 50
- $120.44
- Price above EMA 50
- SMA 200
- $79.08
- Price above SMA 200
- EMA 200
- $92.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$2.92 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAL5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
GRALGrail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
GRAL2 Growth Stocks to Buy in October
2 Growth Stocks to Buy in October
GRAL
Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
GRAL
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
GRAL
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
GRAL
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
GRAL
Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.
Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.
GRAL
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
GRALNews tone: automated (AI) classification of the article's content, not a price prediction.
About Grail Inc
GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. GRAIL, Inc. has market capitalization Approximately $754 million. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Joshua J. Ofman M.D., M.S.H.S | CEO & Director | 1965 |
| Mr. Aaron Freidin | CFO & Head of Corporate Development | 1979 |
| Mr. Robert P. Ragusa | Advisor | 1960 |
| Mr. Paul Ciccolella | Senior Vice President of Global Development & Operations | — |
| Dr. Satnam Alag Ph.D. | Chief Technology Officer | — |
| Sir Harpal S. Kumar M.A., M.B.A., MEng | Chief Scientific Officer and President of Global Clinical & Medical Affairs | — |
| Mr. Abram Barth J.D., M.P.H. | Chief Legal Officer & Corporate Secretary | — |
| Ms. Trish Rowland | Senior Vice President of Corporate Communications | — |
| Ms. Alison Highlander | Chief People Officer | — |
| Mr. Andrew John Partridge | Chief Growth Officer | 1969 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.44
- MACD 12/26/9
- 1.06
- EMA 9 of MACD
- 4.41
- MACD histogram
- -3.36
- SMA 50
- $119.33
- Price above SMA 50
- EMA 50
- $120.44
- Price above EMA 50
- SMA 200
- $79.08
- Price above SMA 200
- EMA 200
- $92.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $100.00
- Average
- $136.44
- High
- $180.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -9.6 | +2.8 | -15.2 | +3.8 | +2.4 | +29.2 | -4.7 | |||||
| 2025 | +69.0 | +33.7 | -29.7 | +37.5 | +18.2 | +37.1 | -30.5 | +0.0 | +87.1 | +48.1 | +22.9 | -12.9 |
| 2026 | +10.1 | -48.7 | -1.8 | +1.6 | +32.6 | +6.0 | +0.7 | +13.0 | +75.6 | +8.2 | -6.7 |
